Back to News
Top StoriesMarketWatch5h ago

Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s strategy

The drugmaker, best known for developing weight-loss and diabetes drugs, failed to excite investors hoping for a turnaround.

Read Full Article on MarketWatch

Content sourced from MarketWatch. Not financial advice.